Kimryn Rathmell

The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists.

The discovery that kidney cells with mutations in a certain gene are sensitive to therapies called PI3K inhibitors opens new opportunities for applying precision medicine to cancer treatment.

A new grant from the National Cancer Institute (NCI) will fund an intensively mentored training experience for clinical fellows at Vanderbilt University Medical Center for the next five years.

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.

Four faculty members of Vanderbilt University School of Medicine were among 78 physician-scientists inducted into The American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:

With last week’s election of Lorraine Ware, MD, as vice president of the American Society for Clinical Investigation (ASCI), two faculty members of the Vanderbilt University School of Medicine are among the current officers of the elite physician-scientist honor society.

Investigators at Vanderbilt-Ingram Cancer Center (VICC) and the Virginia Tech Carilion Research Institute (VTCRI) have revealed a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.